<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937855</url>
  </required_header>
  <id_info>
    <org_study_id>81970067</org_study_id>
    <nct_id>NCT04937855</nct_id>
  </id_info>
  <brief_title>The Mechanism of lncRNA NEAT1 in Alleviating Acute Respiratory Distress Syndrome Through miR-27b Regulated Nrf2 Pathway</brief_title>
  <official_title>The Mechanism of lncRNA NEAT1 in Alleviating Acute Respiratory Distress Syndrome Through miR-27b Regulated Nrf2 Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The acute respiratory distress syndrome, formerly known as the acute lung injury (ARDS/ALI),&#xD;
      is a critical illness with high mortality due to the lack of effective treatment. The&#xD;
      pathogenesis of ARDS/ALI has not been fully elucidated. Nuclear factor E2-related factor 2&#xD;
      (Nrf2) plays a key role in regulating lung inflammation and oxidative stress which are&#xD;
      closely related to lung injury in ARDS/ALI, but its regulatory mechanism remains unclear. The&#xD;
      investigator's provious study shown that microRNA-27b (miR-27b) downregulated Nrf2 to&#xD;
      aggravate lung inflammation and histological injury. Furthermore, in lipopolysaccharide&#xD;
      (LPS)-induced cell (J774A.1) inflammation model, miR-27b was upregulated while the long&#xD;
      non-coding RNA (lncRNA) NEAT1 was downregulated, the putative binding sites of lncRNA NEAT1&#xD;
      and miR-27b were successfully predicted by bioinformatics approach. Thus, the investigators&#xD;
      propose that NEAT1 plays as a competing endogenous RNA (ceRNA) to adsorb miR-27b and liberate&#xD;
      Nrf2, therefore, to attenuate lung inflammation and related lung injury in ARDS/ALI. This&#xD;
      project aims to explore the role of the lncRNA NEAT1/ mir-27b /Nrf2 signal axis in the&#xD;
      development and treatment of ARDS/ALI in patients, as well as in LPS-induced ALI animal and&#xD;
      cell models by using bioinformatics, molecular biology, histomorphology and clinical&#xD;
      phenotype approaches, and to clarify the new mechanism in ARDS/ALI development and to provide&#xD;
      new therapeutic targets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collect blood and BALF from 400 ARDS patients at different time (at check-in, 24, 48 and 72 h&#xD;
      after check-in the hospital) and 25 gender and age matching healthy controls. Use RT-PCR to&#xD;
      detect the expression of lncRNA NEAT1、miR-27b and Nrf2 in blood and BALF of ARDS patients and&#xD;
      health controls. The expressions of inflammatory and oxidative stress associated factors&#xD;
      (NLRP3、NF-κB-P65、 p-P65、IκB、p-IκB、HO-1、NQO1、caspase-1、IL-1β、IL-6、IL-18、TNF-α) will be&#xD;
      detected by western blot、ELISA and RT-PCR. Moreover, flow cytometry will be adopted to&#xD;
      measure the numbers and kinds of cells in BALF. Then, analyze the differences of the&#xD;
      expressions of lncRNA NEAT1、miR-27b and Nrf2 in the groups. To explore the correlation of&#xD;
      expressions of lncRNA NEAT1、miR-27b and Nrf2 with inflammation and oxidative stress in the&#xD;
      groups. Finally, to declare the relative of lncRNA NEAT1、miR-27b and Nrf2 with the time of&#xD;
      mechanical ventilation, severity and mortality in 28 days of ARDS patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The expression of lncRNA NEAT1 in blood and BALF in all groups</measure>
    <time_frame>up to 24 day</time_frame>
    <description>Use RT-PCR to measure the expression of lncRNA NEAT1 in blood and BALF in all groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The expression of miR-27b in blood and BALF in all groups</measure>
    <time_frame>up to 3 day</time_frame>
    <description>Use RT-PCR to measure the expression of miR-27b in blood and BALF in all groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The expression of Nrf2 in blood and BALF in all groups</measure>
    <time_frame>up to 3 day</time_frame>
    <description>Use RT-PCR and Wsetern blot to measure the expression of Nrf2 in blood and BALF in all groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The expression of inflammatory factors(IL-1β、IL-6、IL-18、TNF-α) in blood and BALF in all groups</measure>
    <time_frame>up to 3 day</time_frame>
    <description>Use RT-PCR and ELISA to measure the expression of inflammatory factors(IL-1β、IL-6、IL-18、TNF-α) in blood and BALF in all groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The expression of oxidative stress associated factors in blood and BALF in all groups</measure>
    <time_frame>up to 3 day</time_frame>
    <description>Use Western blot to measure the expression of oxidative stress associated factors(NLRP3、NF-κB-P65、 p-P65、IκB、p-IκB、HO-1、NQO1、caspase-1) in blood and BALF in all groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The numbers and kinds of inflammatory cells in BALF and blood in all groups</measure>
    <time_frame>up to 3 day</time_frame>
    <description>Use flow cytometry to detect the number of inflammatory cells in BALF and blood in all groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The kinds of inflammatory cells in BALF and blood in all groups</measure>
    <time_frame>up to 3 day</time_frame>
    <description>Use flow cytometry to detect the kinds of inflammatory cells(neutrophile、macrophage、 lymphocyte) in BALF and blood in all groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time of mechanical ventilation of patients in ARDS groups</measure>
    <time_frame>up to28 day</time_frame>
    <description>Record the time of mechanical ventilation of patients in ARDS groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The severity of ARDS patients in ARDS groups</measure>
    <time_frame>up to 28 day</time_frame>
    <description>Record the severity(PaO2/FiO2、OI、S/F、OSI) of ARDS patients in ARDS groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the mortality in 28 days of ARDS patients</measure>
    <time_frame>up to 28 day</time_frame>
    <description>Record the mortality in 28 days of ARDS patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The differences and correlation of the expressions of lncRNA NEAT1、miR-27b and Nrf2 in the groups</measure>
    <time_frame>up to 28 day</time_frame>
    <description>Analyse the differences of the expressions of lncRNA NEAT1、miR-27b and Nrf2 in the groups, and to explore the relations between the three(lncRNA NEAT1、miR-27b and Nrf2) in different groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation of expressions of lncRNA NEAT1、miR-27b and Nrf2 with inflammation and oxidative stress in the groups.</measure>
    <time_frame>up to 28 day</time_frame>
    <description>To explore the correlation of expressions of lncRNA NEAT1、miR-27b and Nrf2 with inflammation and oxidative stress in the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relative of lncRNA NEAT1、miR-27b and Nrf2 with the time of mechanical ventilation, severity and mortality in 28 days of ARDS patients</measure>
    <time_frame>up to 28 day</time_frame>
    <description>To declare the relative of lncRNA NEAT1、miR-27b and Nrf2 with the time of mechanical ventilation, severity and mortality in 28 days of ARDS patients</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">425</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>25 gender and age matching healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARDS group 1</arm_group_label>
    <description>100 ARDS patients at the time of check in hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARDS group 2</arm_group_label>
    <description>100 ARDS patients at the time of 24h after check in hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARDS group 3</arm_group_label>
    <description>100 ARDS patients at the time of 48h after check in hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARDS group 4</arm_group_label>
    <description>100 ARDS patients at the time of 72h after check in hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>ARDS group 1</arm_group_label>
    <arm_group_label>ARDS group 2</arm_group_label>
    <arm_group_label>ARDS group 3</arm_group_label>
    <arm_group_label>ARDS group 4</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and BALF will be stored at -70˚C&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We included ARDS patients from RICU、EICU、SICU、CCU in Beijing Anzhen hospital between 2020&#xD;
        and 2022&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        We included patients with acute respiratory distress according to 2012 ARDS Berlin new&#xD;
        definition (Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA, 2012,&#xD;
        307(23):2526).&#xD;
&#xD;
          -  Acute or progressive dyspnea within 1 week with identify cause;&#xD;
&#xD;
          -  Chest radiograph/chest CT showed double lung infiltration, which could not be fully&#xD;
             explained by pleural effusion, atelectasis, or nodules;&#xD;
&#xD;
          -  Respiratory failure cannot be fully explained by heart failure and fluid overload;&#xD;
&#xD;
          -  Hypoxemia, partial pressure of oxygen in arterial blood (PaO2)/oxygen fraction in air&#xD;
             (FIO2) &lt;150 mm Hg under PEEP ≥5 cm H2O, (mild ARDS: 200mmHg&lt;PaO2/FiO2≤300mmHg,&#xD;
             moderate ARDS: 100mmHg&lt;PaO2/FiO2≤200mmHg, severe ARDS: PaO2/FiO2≤100mmHg);&#xD;
&#xD;
          -  18~70 years old;&#xD;
&#xD;
          -  Agree to participate in the trial, and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years old;&#xD;
&#xD;
          -  Time of hospital stay &lt;24 h;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Using V-V ECOM;&#xD;
&#xD;
          -  Cardiac index &lt;1.5L·ml.min-1.m-2;&#xD;
&#xD;
          -  Pulmonary resection;&#xD;
&#xD;
          -  Pulmonary embolism ;&#xD;
&#xD;
          -  Refused to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Respiratory and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669.</citation>
    <PMID>22797452</PMID>
  </reference>
  <reference>
    <citation>Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907. Review.</citation>
    <PMID>29466596</PMID>
  </reference>
  <reference>
    <citation>Lu MC, Ji JA, Jiang ZY, You QD. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev. 2016 Sep;36(5):924-63. doi: 10.1002/med.21396. Epub 2016 May 18. Review.</citation>
    <PMID>27192495</PMID>
  </reference>
  <reference>
    <citation>Wei J, Chen G, Shi X, Zhou H, Liu M, Chen Y, Feng D, Zhang P, Wu L, Lv X. Nrf2 activation protects against intratracheal LPS induced mouse/murine acute respiratory distress syndrome by regulating macrophage polarization. Biochem Biophys Res Commun. 2018 Jun 7;500(3):790-796. doi: 10.1016/j.bbrc.2018.04.161. Epub 2018 Apr 25.</citation>
    <PMID>29684352</PMID>
  </reference>
  <reference>
    <citation>Liu Q, Lv H, Wen Z, Ci X, Peng L. Isoliquiritigenin Activates Nuclear Factor Erythroid-2 Related Factor 2 to Suppress the NOD-Like Receptor Protein 3 Inflammasome and Inhibits the NF-κB Pathway in Macrophages and in Acute Lung Injury. Front Immunol. 2017 Nov 9;8:1518. doi: 10.3389/fimmu.2017.01518. eCollection 2017.</citation>
    <PMID>29163554</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Song M, Zhu G, Xi X, Li K, Wu C, Huang L. Corynoline attenuates LPS-induced acute lung injury in mice by activating Nrf2. Int Immunopharmacol. 2017 Jul;48:96-101. doi: 10.1016/j.intimp.2017.04.029. Epub 2017 May 6.</citation>
    <PMID>28486213</PMID>
  </reference>
  <reference>
    <citation>Rajasekaran S, Pattarayan D, Rajaguru P, Sudhakar Gandhi PS, Thimmulappa RK. MicroRNA Regulation of Acute Lung Injury and Acute Respiratory Distress Syndrome. J Cell Physiol. 2016 Oct;231(10):2097-106. doi: 10.1002/jcp.25316. Epub 2016 Feb 4. Review.</citation>
    <PMID>26790856</PMID>
  </reference>
  <reference>
    <citation>Wu CT, Huang Y, Pei ZY, Xi X, Zhu GF. MicroRNA-326 aggravates acute lung injury in septic shock by mediating the NF-κB signaling pathway. Int J Biochem Cell Biol. 2018 Aug;101:1-11. doi: 10.1016/j.biocel.2018.04.019. Epub 2018 May 1. Erratum in: Int J Biochem Cell Biol. 2021 Mar;132:105922.</citation>
    <PMID>29727715</PMID>
  </reference>
  <reference>
    <citation>Ling Y, Li ZZ, Zhang JF, Zheng XW, Lei ZQ, Chen RY, Feng JH. MicroRNA-494 inhibition alleviates acute lung injury through Nrf2 signaling pathway via NQO1 in sepsis-associated acute respiratory distress syndrome. Life Sci. 2018 Oct 1;210:1-8. doi: 10.1016/j.lfs.2018.08.037. Epub 2018 Aug 17.</citation>
    <PMID>30121199</PMID>
  </reference>
  <reference>
    <citation>Ding L, Ni J, Yang F, Huang L, Deng H, Wu Y, Ding X, Tang J. Promising therapeutic role of miR-27b in tumor. Tumour Biol. 2017 Mar;39(3):1010428317691657. doi: 10.1177/1010428317691657. Review.</citation>
    <PMID>28351320</PMID>
  </reference>
  <reference>
    <citation>Zhou R, Gong AY, Eischeid AN, Chen XM. miR-27b targets KSRP to coordinate TLR4-mediated epithelial defense against Cryptosporidium parvum infection. PLoS Pathog. 2012;8(5):e1002702. doi: 10.1371/journal.ppat.1002702. Epub 2012 May 17.</citation>
    <PMID>22615562</PMID>
  </reference>
  <reference>
    <citation>Signorelli SS, Volsi GL, Pitruzzella A, Fiore V, Mangiafico M, Vanella L, Parenti R, Rizzo M, Volti GL. Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress. Angiology. 2016 Nov;67(10):945-950. doi: 10.1177/0003319716638242. Epub 2016 Jul 11.</citation>
    <PMID>26980776</PMID>
  </reference>
  <reference>
    <citation>Li T, Cao H, Zhuang J, Wan J, Guan M, Yu B, Li X, Zhang W. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin Chim Acta. 2011 Jan 14;412(1-2):66-70. doi: 10.1016/j.cca.2010.09.029. Epub 2010 Sep 29.</citation>
    <PMID>20888330</PMID>
  </reference>
  <reference>
    <citation>Huang Y, Huang L, Zhu G, Pei Z, Zhang W. Downregulated microRNA-27b attenuates lipopolysaccharide-induced acute lung injury via activation of NF-E2-related factor 2 and inhibition of nuclear factor κB signaling pathway. J Cell Physiol. 2019 May;234(5):6023-6032. doi: 10.1002/jcp.27187. Epub 2018 Dec 24.</citation>
    <PMID>30584668</PMID>
  </reference>
  <reference>
    <citation>Song YX, Sun JX, Zhao JH, Yang YC, Shi JX, Wu ZH, Chen XW, Gao P, Miao ZF, Wang ZN. Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion. Nat Commun. 2017 Aug 18;8(1):289. doi: 10.1038/s41467-017-00304-1. Erratum in: Nat Commun. 2021 May 19;12(1):3149.</citation>
    <PMID>28819095</PMID>
  </reference>
  <reference>
    <citation>Yan B, Yao J, Liu JY, Li XM, Wang XQ, Li YJ, Tao ZF, Song YC, Chen Q, Jiang Q. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 2015 Mar 27;116(7):1143-56. doi: 10.1161/CIRCRESAHA.116.305510. Epub 2015 Jan 13.</citation>
    <PMID>25587098</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013 Apr 15;25(1):69-80. doi: 10.1016/j.devcel.2013.03.002. Epub 2013 Mar 28.</citation>
    <PMID>23541921</PMID>
  </reference>
  <reference>
    <citation>Xiong DD, Li ZY, Liang L, He RQ, Ma FC, Luo DZ, Hu XH, Chen G. The LncRNA NEAT1 Accelerates Lung Adenocarcinoma Deterioration and Binds to Mir-193a-3p as a Competitive Endogenous RNA. Cell Physiol Biochem. 2018;48(3):905-918. doi: 10.1159/000491958. Epub 2018 Jul 23. Erratum in: Cell Physiol Biochem. 2020;54(3):508-509.</citation>
    <PMID>30036873</PMID>
  </reference>
  <reference>
    <citation>Wang L, Xia JW, Ke ZP, Zhang BH. Blockade of NEAT1 represses inflammation response and lipid uptake via modulating miR-342-3p in human macrophages THP-1 cells. J Cell Physiol. 2019 Apr;234(4):5319-5326. doi: 10.1002/jcp.27340. Epub 2018 Sep 27.</citation>
    <PMID>30259979</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Guangfa Zhu</investigator_full_name>
    <investigator_title>Director, Head of Respiratory and Critical Medicine Department</investigator_title>
  </responsible_party>
  <keyword>long non-coding RNA NEAT1</keyword>
  <keyword>microRNA-27b</keyword>
  <keyword>nuclear factor E2-related factor 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

